↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Neurocrine Biosciences$NBIX · filed: grew revenue 21.4% in FY2025 to $2.9BNew shipTrillion Score 590Fall Risk MediumNext year $3.1B–$3.8B sealedCheck ▾Close ▴
What Neurocrine Biosciences filed
Grew revenue 21.4% in FY2025 to $2.9 billion, operating margin 21.6% against a -15.8% median for biological products, (no diagnostic substances), equity 70.2% of assets. Every figure links to the filing it came from on Neurocrine Biosciences’s card. New ship: no warning signs. Trillion Score 590, #11 of 182 in its field; Fall Risk Medium (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $3.1B and $3.8B, an 80% range sealed on 27 Sept 2026 · receipt #9195dc · graded in public by the revenue in Neurocrine Biosciences’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Neurocrine spent **$575M** to buy commercial revenue and rare disease optionality, not R&D risk—VYKAT XR folds into existing infrastructure with minimal incremental cost.
$575 million
acquisition of Soleno Therapeutics
$325 million
upfront cash with
$250 million
in contingent payments tied to regulatory and commercial milestones…
$50-70 million
in VYKAT XR revenue for 2025
Neurocrine Biosciences disclosed precise financial terms and integration milestones for its $575 million acquisition of Soleno Therapeutics, centering on VYKAT XR (diazoxide choline) for Prader-Willi syndrome. The company provided updated revenue projections and regulatory timelines that position the deal as platform extension rather than therapeutic pivot.
Neurocrine structured the transaction as $325 million upfront cash with $250 million in contingent payments tied to regulatory and commercial milestones through 2027. VYKAT XR entered the portfolio with FDA approval already secured in March 2024 and commercial launch underway. Neurocrine guided to $50-70 million in VYKAT XR revenue for 2025, reflecting four full quarters of integrated sales force effort. The company specified that peak revenue potential sits north of $500 million annually, assuming label expansion into pediatric hyperphagia indications currently in Phase III development.
The acquisition matters because Neurocrine operates a commercial infrastructure built for chronic CNS conditions—tardive dyskinesia, Parkinson's, endometriosis—with field teams already calling on neurology and psychiatry practices that overlap substantially with Prader-Willi treatment centers. VYKAT XR slots into existing relationships rather than requiring new channel development. Soleno's orphan drug brought 1,200 patients on therapy at acquisition close, a base Neurocrine expects to double within eighteen months by leveraging its payor contracting muscle and nurse educator network. The company disclosed it will fold VYKAT XR into the same specialty pharmacy hub model that supports INGREZZA, its $1.9 billion tardive dyskinesia franchise, eliminating redundant patient support infrastructure.
The deal also loads optionality into Neurocrine's mid-stage pipeline without requiring internal R&D build-out in rare metabolic disease. Soleno's pediatric trial for hyperphagia in hypothalamic obesity reads out in Q3 2026, with potential for $150-200 million in additional peak revenue if data support label expansion. Neurocrine management specified on the acquisition call that it will not increase its R&D budget to support the VYKAT program—existing clinical operations capacity absorbs the workload. That discipline matters to allocators because it signals the company views this as commercial tuck-in, not a costly therapeutic bet requiring fresh capital deployment.
Operators and allocators should track three near-term events. First, Neurocrine reports Q1 2025 earnings in late April, which will include the first full quarter of integrated VYKAT XR sales and revised full-year revenue guidance that incorporates Soleno's contribution. Second, the pediatric hypothalamic obesity trial hits its enrollment target in Q2 2025, setting up the Q3 2026 readout that determines whether the $250 million milestone payments trigger. Third, watch for any shifts in Neurocrine's capital allocation stance—management has historically returned excess cash via buybacks, but this acquisition consumed $325 million in balance sheet liquidity, reducing near-term repurchase capacity.
Neurocrine ended Q4 2024 with $1.1 billion in cash and investments, down from $1.5 billion pre-acquisition, leaving roughly $800 million in dry powder after accounting for working capital needs.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor Q1 earnings in April for VYKAT integration costs—acquisition should be accretive by Q3 if rare disease sales infrastructure scales as guided.
For the operator
Pediatric trial readout in Q3 2026 determines whether $250M milestones hit—track enrollment pace through Q2 2025 for early signal on timeline risk.
For the house
NBIX position sized for platform durability, not acquisition upside—maintain hold through April earnings, reassess if VYKAT guidance disappoints or integration costs surprise.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
